BioVersys Future Growth
Future criteria checks 2/6
BioVersys's earnings are forecast to decline at 13.5% per annum while its annual revenue is expected to grow at 73.6% per year. EPS is expected to decline by 13.6% per annum. Return on equity is forecast to be -141.7% in 3 years.
Key information
-13.5%
Earnings growth rate
-13.55%
EPS growth rate
| Pharmaceuticals earnings growth | 9.5% |
| Revenue growth rate | 73.6% |
| Future return on equity | -141.65% |
| Analyst coverage | Low |
| Last updated | 23 Mar 2026 |
Recent future growth updates
Recent updates
Global Antibiotic Partnerships And New Reimbursement Models Will Support Strong Future Potential
Catalysts About BioVersys BioVersys is a clinical stage biopharmaceutical company focused on antibiotics targeting severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Is BioVersys (VTX:BIOV) A Risky Investment?
Sep 27
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 39 | -30 | N/A | N/A | 2 |
| 12/31/2027 | 6 | -31 | -39 | -39 | 3 |
| 12/31/2026 | 4 | -25 | -26 | -26 | 2 |
| 12/31/2025 | 3 | -22 | -22 | -22 | N/A |
| 9/30/2025 | 2 | -21 | -19 | -19 | N/A |
| 6/30/2025 | 1 | -19 | -17 | -17 | N/A |
| 3/31/2025 | 1 | -19 | -16 | -16 | N/A |
| 12/31/2024 | 1 | -19 | -16 | -16 | N/A |
| 12/31/2023 | 1 | -18 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOV's revenue (73.6% per year) is forecast to grow faster than the Swiss market (4.4% per year).
High Growth Revenue: BIOV's revenue (73.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOV is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/24 20:36 |
| End of Day Share Price | 2026/03/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioVersys AG is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jelena Milovic | Citigroup Inc |
| Jyoti Prakash | Edison Investment Research |
| Raghuram Selvaraju | H.C. Wainwright & Co. |